Actively Recruiting
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-02-05
200
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.
CONDITIONS
Official Title
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Documented germline pathogenic or likely pathogenic mutation in BRCA1, BRCA2, ATM, or PALB2
- If no history of pancreatic cancer in a first or second degree relative, age 50 years or older
- If there is a history of pancreatic cancer in a first or second degree relative, minimum age is 10 years younger than the age of onset of the youngest affected relative
You will not qualify if you...
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19004
Actively Recruiting
Research Team
B
Bryson Katona, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here